Relay Therapeutics Inc. (RLAY): Find Out What Insiders Are Doing


Relay Therapeutics Inc. (NASDAQ:RLAY) traded with an addition of $0.7 to close at $14.86 on Thursday, an upside of 4.94 percent. An average of 943,158 shares of common stock have been traded in the last five days. There was a fall of -$0.04 in the past week, and it reached a new high 4 times over the past 12 months. The last 20 days have seen an average of 1,432,950 shares traded, while the 50-day average volume stands at 1,073,480.

RLAY stock has decreased by -23.09% in the last month. The company shares reached their 1-month lowest point of $14.00 on 12/29/22. With the stock rallying to its 52-week high on 04/04/22, shares of the company touched a low of $12.65 and a high of $35.36 in 52 weeks. It has reached a new high 3 times so far this year and lost -53.89% or -$15.93 in price. In spite of this, the price is down -57.98% from the 52-week high.

Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.


Insider Transactions

RLAY stock investors should be aware that Relay Therapeutics Inc. (RLAY) stock had its last reported insider trading activity 2 days ago on Dec 27. In this transaction, the insider spent $6,448. President, R&D, Bergstrom Donald A, disposed of 980 shares at a price of $14.49 on Dec 27. The insider now owns more than $14,200 worth of shares. Prior to that, Chief Legal Officer Adams Brian went on to Sale 295 shares at $14.49 each on Dec 27. An amount of $4,275 was transacted.

Valuation Metrics

Relay Therapeutics Inc. (RLAY) has a trailing price-to-sales (P/S) ratio at 1045.59, the price-to-book (PB) ratio at 1.57.

Financial Health

The quick ratio of Relay Therapeutics Inc. for the three months ended September 29 was 15.20, and the current ratio was 15.20, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending September 29. Its gross profit as reported stood at $367.73 million compared to revenue of $3.03 million.

For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Relay Therapeutics Inc.’s return on assets was -28.90%.

Earnings Surprise

In the quarter under review, the net income was down than the previous quarter. The company posted a net income of -$84.17 million in the quarter, while revenues of -$76.79 million were shrunk -129.77%. The analyst consensus anticipated Relay Therapeutics Inc.’s latest quarter earnings to come in at -$0.71 per share, but it turned out to be -$0.76, a -7.00% surprise. For the quarter, EBITDA amounted to -$84.52 million. Shareholders own equity worth $120.89 million.

Technical Picture

From a technical analysis perspective, let’s take a brief look at Relay Therapeutics Inc. (RLAY) price momentum. RSI 9-day as of the close on 28 December was 33.88%, suggesting the stock is Neutral, with historical volatility in this time frame at 54.29%.

As of today, RLAY’s price is $14.62 -0.27% or -$0.04 from its 5-day moving average. RLAY is currently trading -20.45% lower than its 20-day SMA and -25.62% lower than its 100-day SMA. However, the stock’s current price level is -29.35% below the SMA50 and -35.51% below the SMA200.

The stochastic %K and %D were 10.40% and 7.20%, respectively, and the average true range (ATR) was 0.98. With the 14-day stochastic at 19.60% and the average true range at 1.03, the RSI (14) stands at 33.96%. The stock has reached -0.72 on the 9-day MACD Oscillator while the 14-day reading was at -1.37.

Analyst Ratings

Barclays launched coverage on Relay Therapeutics Inc. (NASDAQ: RLAY) in its analyst report released on September 30, 2022. The firm assigned the stock an Equal weight rating. The consensus rating for Relay Therapeutics Inc. (RLAY) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell RLAY, while 1 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 9 others rate it as a “buy”.

What is RLAY’s price target for the next 12 months?

Analysts predict a range of price targets between $23.00 and $45.00, with a median target of $40.00. Taking a look at these predictions, the average price target given by analysts for Relay Therapeutics Inc. (RLAY) stock is $39.56.


Please enter your comment!
Please enter your name here